Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a contract development and manufacturing organization specializing in providing integrated services to the pharmaceutical and medical device industries. As LFCR prepares to release its quarterly earnings on April 3, 2025, Wall Street anticipates an earnings per share loss of $0.14 and revenue of around $33.2 million.
LFCR's financial results for the third quarter of fiscal year 2025 will be shared after the market closes. Following the release, the company's senior management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and recent corporate developments. This webcast will be available live and archived for 30 days on the company's Investor Events & Presentations page.
Despite a negative price-to-earnings (P/E) ratio of -17.35, LFCR's price-to-sales ratio is 2.04. This suggests that investors are willing to pay $2.04 for every dollar of the company's sales. The enterprise value to sales ratio is 2.97, reflecting the company's valuation relative to its sales.
LFCR's enterprise value to operating cash flow ratio is significantly high at around 1100, indicating low operating cash flow relative to its enterprise value. The earnings yield is negative at approximately -5.76%, highlighting the company's current unprofitability. The debt-to-equity ratio is notably high at about 8.50, suggesting heavy leverage.
However, LFCR's current ratio is approximately 2.32, indicating a strong ability to cover short-term liabilities with short-term assets. This suggests that despite its challenges, LFCR maintains a solid liquidity position, which is crucial for its ongoing operations and financial stability.
